Order Article Reprints

Verkleij CPM, Jhatakia A, Broekmans MEC, Frerichs KA, Zweegman S, Mutis T, Bezman NA, van de Donk NWCJ. Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. Cancers. 2020; 12(12):3713. https://doi.org/10.3390/cancers12123713

Verkleij, Christie P. M., Amy Jhatakia, Marloes E. C. Broekmans, Kristine A. Frerichs, Sonja Zweegman, Tuna Mutis, Natalie A. Bezman, and Niels W. C. J. van de Donk. 2020. "Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies" Cancers 12, no. 12: 3713. https://doi.org/10.3390/cancers12123713

Verkleij, C. P. M., Jhatakia, A., Broekmans, M. E. C., Frerichs, K. A., Zweegman, S., Mutis, T., Bezman, N. A., & van de Donk, N. W. C. J. (2020). Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. Cancers, 12(12), 3713. https://doi.org/10.3390/cancers12123713